Vericor

Ipamorelin is among the most frequently cited names in growth-hormone-secretagogue (GH secretagogue) research, largely because of one real, published, and comparatively well-documented property: unlike several older compounds in its class, it was reported in controlled pharmacology studies to stimulate growth hormone (GH) release with minimal effect on cortisol, adrenocorticotropic hormone (ACTH), or prolactin. That selectivity

SS-31 — known in the pharmaceutical literature as elamipretide — is a mitochondria-targeting tetrapeptide with an unusually deep clinical-trial record for a compound in the research-peptide space, including a genuine 2025 FDA approval of a related prescription drug product for one narrow rare-disease indication. This guide is written for laboratory researchers, institutional buyers, and scientific